Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV

Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV

Current HIV cure-focused clinical trials rely on analytic treatment interruption (ATI) to evaluate post-treatment control (PTC). Here, combining untargetted metabolomics and glycomics in two HIV clinical cohorts, in vitro assays, and machine learning, the authors identify and validate metabolic and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Leila B. Giron, Clovis S. Palmer, Qin Liu, Xiangfan Yin, Emmanouil Papasavvas, Radwa Sharaf, Behzad Etemad, Mohammad Damra, Aaron R. Goldman, Hsin-Yao Tang, Rowena Johnston, Karam Mounzer, Jay R. Kostman, Pablo Tebas, Alan Landay, Luis J. Montaner, Jeffrey M. Jacobson, Jonathan Z. Li, Mohamed Abdel-Mohsen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/8389144aeb1a4d6d950f9fd144f01fe1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Current HIV cure-focused clinical trials rely on analytic treatment interruption (ATI) to evaluate post-treatment control (PTC). Here, combining untargetted metabolomics and glycomics in two HIV clinical cohorts, in vitro assays, and machine learning, the authors identify and validate metabolic and glycomic biomarkers linked to inflammatory pathways and HIV latency reactivation associated with PTC, suggesting non-invasive biomarkers as an alternative to predict HIV remission.

Ejemplares similares